As of March 2024, more than 350,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 1,000,000 patient years1
>9,900 patients in clinical trials and open-label extension
>350,000 patients with post-marketing experience
As of March 2024, more than 350,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 1,000,000 patient years1
>9,900 patients in clinical trials and open-label extension
>350,000 patients with post-marketing experience
References
1. Roche data on file: post-marketing experience and clinical trials data cut-off Mar 2024